A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients
Completed · Not applicable
Conditions studied: HIV Infections, Psoriasis
In brief
To evaluate the feasibility of Retrovir (AZT) in the treatment of psoriasis in HIV antibody positive patients. Retrovir has been shown to be effective in the treatment of AIDS. In addition, the administration of AZT appears to have induced a remission of psoriasis in one case study. In light of AZT's antiviral activity and potential effectiveness as an agent for the treatment of psoriasis, this would be the most likely treatment for HIV positive, psoriatic patients whose disease progresses quickly.
Key facts
- Study ID
- NCT00002286
- Run by
- Glaxo Wellcome
- Last updated by the study team
- 2005-06-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Study participants must have biopsy-proven psoriasis with 3 distinct psoriatic lesions. (Biopsy-proven Reiter's syndrome patients with 3 distinct cutaneous lesions may be included.) Documented HIV antibody (by federally licensed ELISA test) positive patients.
- Prior Medication:
- Allowed:
- Zidovudine (AZT).
You may not qualify if…
- Co-existing Condition:
- Patients with the following are excluded:
- Presence of any active opportunistic infection.
- Presence of any AIDS-defining neoplasms (excluding Kaposi's sarcoma) such as central nervous system (CNS) lymphoma.
- Known hypersensitivity to zidovudine (AZT).
- Impaired renal function.
- Significant hepatic dysfunction.
- Concurrent Medication:
- Excluded:
- Topical steroid, anthralin, or tar preparations. Etretinate, methotrexate, or psoralen ultraviolet A (PUVA) therapy. Psoriatic treatment such as systemic agents or topical steroids (emollients used distal to the control lesions and antipruritic shampoos are admissible).
- Patients with the following are excluded:
- Presence of any active opportunistic infection.
- Presence of any AIDS-defining neoplasms (excluding Kaposi's sarcoma) such as central nervous system (CNS) lymphoma.
- Known hypersensitivity to zidovudine (AZT).
- Impaired renal function.
- Significant hepatic dysfunction.
- Prior Medication:
- Excluded:
- Other antiretroviral agents (e.g., suramin, ribavirin, HPA-23, dideoxycytidine).
- Excluded within 2 weeks of study entry:
- Topical steroid, anthralin, or tar preparations.
- Any other experimental therapy drugs which cause significant bone marrow suppression such as antifolates or pyrimethamine.
- Cytolytic chemotherapy.
- Drugs which cause significant nephrotoxicity or hepatotoxicity.
- Rifampin or rifampin derivatives.
Where it is running
- Glaxo Wellcome Inc — Research Triangle Park, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.